Snowball logo
logo
XTLB

XTL Biopharmaceuticals Ltd

XTLB • NASDAQ
$1.82-$0.20  (9.9%)
Estimate
EPS
-0.36
Beta
0.425
About the company
Ticker
XTLB
ISIN
US98386D3070
Country
Israel
Sector (GICS)
Healthcare
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.

Frequently asked questions

What sector does XTL Biopharmaceuticals Ltd (XTLB) operate in?

XTL Biopharmaceuticals Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.

What is XTL Biopharmaceuticals Ltd (XTLB) current stock price?

As of the latest data, XTL Biopharmaceuticals Ltd stock price is $1.82, with a previous close of $2.02. XTL Biopharmaceuticals Ltd lost -$0.20 in the last trading session, representing a -9.9% loss.

What is XTL Biopharmaceuticals Ltd (XTLB) current market capitalization?

XTL Biopharmaceuticals Ltd market cap is approximately 4.47 million.

What is XTL Biopharmaceuticals Ltd (XTLB) Earnings Per Share (EPS)?

The trailing EPS is -$0.36.

Does XTL Biopharmaceuticals Ltd (XTLB) pay dividends?

No. XTL Biopharmaceuticals Ltd does not pay a dividend.

What is XTL Biopharmaceuticals Ltd (XTLB) beta (volatility) score?

XTL Biopharmaceuticals Ltd has a beta of 0.425, indicating lower volatility than the overall market.